Is the price fair?
What HIMS's price assumes
Hims & Hers Health, Inc. did not earn a profit over the last twelve months, so it has no trailing P/E and the price is measured against sales instead: 2.00× revenue.
2.00
Price / sales · no P/E: the last twelve months did not end in a profit
- Free cash flow yield
- 0.81%
Free cash flow yield · Drug Manufacturers - Specialty & Generic median 4.4%
- Growth the price implies
- +30%
Growth the price implies · The price pays for +30% free cash flow growth a year for a decade; revenue has grown +54% a year over the last three.
- Price / book
- 10.6
Price / book · as of 2026-Q1
Details›
- Price / book2026-Q1
- 10.6
- EV / EBIToperating margin −6.0%: the multiple describes the denominator
- not meaningful
- Free cash flow, trailing twelve months
- $62M
- Market capitalisation
- $7.57B
- 3-year revenue growth
- +54%
Multiples from SEC filings and end-of-day closes; implied growth from a reverse discounted cash flow. Group medians across the names Ryufin tracks.
Drug Manufacturers - Specialty & Generic
Ranks #21 of 29 by Smart Score